Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro. This provides an ethical, cost-effective, and predictive alternative to animal testing.
The Gelomics leadership team is composed of experienced professionals. They are dedicated to advancing the company’s vision of transforming drug discovery through innovative 3D cell culture solutions.
An award-winning researcher with 50+ publications and 2,800+ citations. Since 2017, Dr. Meinert has secured $12M+ in funding, led 17 global product developments, and expanded Gelomics to 23 markets. His work is widely recognized in top-tier scientific journals and biotech innovation.
Peter holds a PhD in the development of novel biomaterials for tissue engineering – the technology and materials behind Gelomics’ first products. A chartered chemical engineer and graduate of the Australian Institute of Company Directors, he brings extensive experience in capital raising, technology development, commercialisation and team growth.
Emma is a Biomedical Science graduate with a strong background in biotechnology and commercial strategy. With experience spanning scientific research, business development, and product management, she has worked globally with pharmaceutical companies to drive efficiency. Now a Sales and Applications Specialist at Gelomics, Emma specializes in advancing 3D cell culture technologies for research and drug discovery.
Leading strategic initiatives to drive the commercialization of cutting-edge 3D cell culture technologies. With over 10 years of experience in marketing and expertise in go-to-market strategy and biotech innovation, she bridges science and business to accelerate adoption. As a UQ MBA candidate, Hayley brings a strong analytical and leadership approach to positioning Gelomics at the forefront of the industry.
Dr. Pawel Mieszczanek leads engineering at Gelomics, developing innovative lab devices and software solutions. With a PhD in engineering and extensive experience in the medical device and biotech industries, he brings expertise in product development, mechatronics, and AI/ML. He is passionate about driving product development and leading high-performing teams.
Farhad is a PhD graduate in Biomedical Engineering from UQ. In 2024, I joined Gelomics as the Lead R&D Scientist. I’m passionate about developing biomaterials for 3D cell culture and studying cell-matrix interactions to advance biomedical applications and improve therapeutic outcomes.
These distinguished leaders in their fields bring a wealth of knowledge and expertise to Gelomics, therefore driving our mission of revolutionizing drug development with cutting-edge 3D cell culture technology.
Oxford University
“Gelomics are developing exciting biomaterials technology that aligns with a sustainable future in biomedical research and development. I look forward to contributing my expertise to advance their ground-breaking work.”
Professor Stevens is the John Black Professor of Bionanoscience at Oxford University, serving in the Institute for Biomedical Engineering and the Department of Physiology, Anatomy, and Genetics. Additionally, she is Deputy Director of the Kavli Institute for Nanoscience Discovery. Holding a PhD from the University of Nottingham and postdoctoral experience at MIT, she led research at Imperial College London and remains part-time faculty. Additionally, she is a Biomaterials Professor at Karolinska Institutet. Recognized for her work in biosensing, regenerative medicine, and therapeutics, she has published over 400 papers and holds numerous patents, including four spin-out companies. Furthermore, Prof. Stevens has received over 40 awards, including the Novo Nordisk Award (2023), and is a Fellow of several prestigious institutions, such as the Royal Society.
Queensland University of Technology (QUT)
“I’m excited to contribute to Gelomics’ pioneering efforts, to support the biomaterials science and tissue engineering and regenerative medicine community with products which allow to strive for reproducibility and enhancement of translational readiness levels of their research endevours.”
Professor Hutmacher, co-founder of Gelomics, and current Director of the Max Planck Queensland Centre for the Materials Science of Extracellular Matrices, is a globally recognised leader in tissue engineering and regenerative medicine. With decades of industrial and academic excellence, Professor Hutmacher has pioneered numerous biomedical innovations. Moreover, he has authored over 500 journal articles, edited 14 books, and holds an h-index of 133 with over 75,000 citations. As a result, his role at Gelomics will leverage his expertise in translating research into commercial and clinical applications, driving biomaterials technology forward.
Queensland University of Technology (QUT)
“I am thrilled to join Gelomics’ Scientific Advisory Board and support the development of innovative, non-animal methodologies that pave the way for more ethical and efficient drug development.”
Professor Klein, also a co-founder of Gelomics, is a distinguished figure in the field of biomedical engineering at the Queensland University of Technology (QUT). As leader of the Cartilage Regeneration Laboratory, he develops regenerative therapies for cartilage defects. His senior QUT roles and 10,000+ citations will be invaluable as Gelomics pioneers innovative, non-animal drug development methodologies.
+61 1800 865 060
Send us an email here
60 Musk Avenue
Kelvin Grove, QLD 4059
Australia
ABN 14 624 623 623
